HEALTH OF WOMAN. 2016.6(112):59–61 
 

The immune phenotype of pregnant women infected with parvovirus B19, a non-immune fetal hydrops: clinical cases 
 

Bondarenko N. P., Lakatosh V. P., Aksonova A. V.

A.A. Bogomolets National Medical University, Kiev

Perinatal center, Kiev

The article analyzes the performance of immunograms of pregnant women in three clinical cases of non-immune fetal hydrops caused by parvovirus B19 infection that resulted in death in 2 cases. Demonstrated that two patients with the normal parameters of humoral immunity, a decrease of quantitative indicators of T-lymphocytes and the main effectors of antiviral cellular immunity – cytotoxic CD8+ lymphocytes and NK-cells as compared with the data of the third patient for which was characterized by the activation of the cellular component of antiviral immunity that is contributed to the effective elimination of the infection and prevent severe fetal losses, which stayed alive. We consider it necessary to focus the attention of physicians on this medical aspect that the functional activity of the immune system of pregnant women is an important factor in case of parvovirus B19 infection which determines the efficiency and speed to overcome the infection and predict its consequences for the child.

Key words: parvovirus B19, non-immune fetal hydrops, immune phenotype.

REFERENCES

1. Barash J, Dushnitzki D, Barak et al. 2003. (TNF) б and its soluble receptor (sTNFR) p75 during acute human parvovirus B19 infection children. Immunol Lett 88:109–12. http://dx.doi.org/10.1016/S0165-2478(03)00075-0

2. Beigi RH, Wiesenfeld HC, Landers DV et al. 2008. High Rate of Severe Fetal Outcomes Associated with Maternal Parvovirus B19 Infection in Pregnancy. Infect Dis Obstet Gynecol. 2008:524601. http://dx.doi.org/10.1155/2008/524601; PMid:18464909 PMCid:PMC2358947

3. Bellini C, Hennekam RCM, Fulcheri E et al. 2009. Etiology of nonimmune hydrops fetalis: A systematic review. Am J Med Genet Part A. 149A:844–51. http://dx.doi.org/10.1002/ajmg.a.32655; PMid:19334091

4. Brown T, Anand A, Ritchie LD, Clewley JP, Reid TMS. 1984. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 2:1033–4. http://dx.doi.org/10.1016/S0140-6736(84)91126-7

5. Cossart YE, Field AM, Cant B, Widdows D. 1975, Jan 11. Parvovirus-like particles in human sera Lancet. 1(7898):72–3. http://dx.doi.org/10.1016/S0140-6736(75)91074-0

6. Daniilidis A, Sidiropoulos K, Panna ZD et al. 2014, Jan. Association of fetal loss with recent parvovirus infection and o ther demographic prognostic risk factors J Obstet Gynaecol. 34(1):40–4. http://dx.doi.org/10.3109/01443615.2013.820269; PMid:24359048

7. Doyle S, Corcoran A. 2006. The Immune Response to Parvovirus B19 Exposure in Previously Seronegative and Seropositive Individuals. J Infect Dis. 194(2):154-158. http://dx.doi.org/10.1086/505226.

8. Enders M, Weidner A, Rosenthal T et al. 2008, Jan 1. Improved Diagnosis of Gestational Parvovirus B19Infection at the Time of Nonimmune Fetal Hydrops. J Infect Dis. 197(1):58–62. http://dx.doi.org/10.1086/524302; PMid:18171285

9. Ergaz Z, Ornoy A. 2006. Parvovirus B19 in pregnancy. Rep Tox; 21:421–435. http://dx.doi.org/10.1016/j.reprotox.2005.01.006; PMid:16580942

10. Giorgio E, De Oronzo MA, Iozza I, Di Natale A et al. 2010. Parvovirus B19 during pregnancy: a review Journal of Prenatal Medicine 4(4):63–66. PMid:22439064 PMCid:PMC3279187

11. Ismail KM, Martin WL, Ghosh S, Whittle MJ, Kilby MD. 2001. Etiology and outcome of hydrops fetalis. J Matern Fetal Med 10(3):175–81. http://dx.doi.org/10.1080/jmf.10.3.175.181-9; PMid:11444786

12. Kailasam C, Brennand J, Cameron AD. 2001. Congenital Parvovirus B19 infection: experience of a recent epidemic. Fetal Diagn Ther 16(1):18–22. http://dx.doi.org/10.1159/000053874; PMid:11125246

13. Kaiser L, Sukosd F, Veszpremi B et al. 2000. Parvovirus B19 infection in hydrops fetalis. Orv Hetil 141(30):1661–5. PMid:10962903

14. Klenerman P, Tolfvenstam T, Price DA et al. 2002. T lymphocyte responses against human parvovirus B19: small virus, big response. Pathol Biol 50:317–25. http://dx.doi.org/10.1016/S0369-8114(02)00306-1

15. Mor G, Abrahams V. 2002. Immunology of implantation. In: Arici, A., editor. Immunology and Allergy Clinics. Philadelphia: W.B. Saunders Company:545–565. http://dx.doi.org/10.1016/s0889-8561(02)00009-7

16. Mor G, Cardenas I. 2010, June. The Immune System in Pregnancy: A Unique Complexity. Am J Reprod Immunol. 63(6):425–433. http://dx.doi.org/10.1111/j.1600-0897.2010.00836.x; PMid:20367629 PMCid:PMC3025805

17. Von Poblotzki A, Gerdes C, Reischl U et al. 1996. Lymphoproliferative responses after infection with human parvovirus B19. J Virol. 70(10):7327–30. PMid:8794392 PMCid:PMC190798

18. Wagner AD, Goronzy JJ, Matteson EL et al. 1995, Mar. Systemic monocyte and T-cell activation in a patient with human parvovirus B19 infection. Mayo Clin Proc. 70(3):261–5. http://dx.doi.org/10.4065/70.3.261; PMid:7861814

19. Yaegashi N, Niinuma T, Chisaka H et al. 1999. Serologic study of human Parvovirus B19 infection in pregnancy in Japan. J Infect 38(1):30–5. http://dx.doi.org/10.1016/S0163-4453(99)90026-9

20. Yurdakцk M. 2014. Non-immune hydrops fetalis. J Pediatr Neonat Individual Med. 3(2):e030214.